Skip to content

4Accepted Sep 9, 4:20 PM ET

Barinthus (BRNS) Director Joseph Scheeren Sells/Converts 134,819 Shares

BRNSBarinthus Biotherapeutics plc.

Accepted (ET)

4:20 PM

Sep 9, 2026

Filed

Sep 9, 2026

Documents

1

Size

18.2 KB

Summary

Barinthus (BRNS) Director Joseph Scheeren Sells/Converts 134,819 Shares

Updated

What Happened

  • Joseph Scheeren, a director of Barinthus Biotherapeutics plc, had multiple dispositions reported on 2026-09-09 totaling 134,819 Barinthus shares (individual lots: 23,000; 34,328; 18,604; 19,197; 19,516; 20,174). The filings show N/A or $0.00 per share and $0 total proceeds because these were dispositions in connection with the company’s merger/scheme of arrangement effective 09/09/2026, not open-market cash sales. Under the merger terms each Barinthus share converted into the right to receive 0.111 shares of Beacon Topco, Inc., so the reported dispositions equate to receipt of roughly 14,965 Topco common shares (134,819 × 0.111). Options that previously related to Barinthus shares were similarly converted/assumed by Topco.

Key Details

  • Transaction date: 2026-09-09 (Effective Time of the Scheme/Merger).
  • Transaction type/codes: D = Disposition to the issuer; several entries are listed as “Derivative” with $0.00 per share (no cash proceeds reported).
  • Shares disposed: 134,819 total (breakdown in filing: 23,000; 34,328; 18,604; 19,197; 19,516; 20,174).
  • Reported proceeds: $0 (reflects conversion/cancellation under merger, not a market sale).
  • Conversion: Each Barinthus share converted into right to receive 0.111 Topco shares (≈14,965 Topco shares total).
  • Options: Outstanding options were converted into options to acquire Topco common stock and assumed by Topco on same terms (per filing footnote).
  • Shares owned after transaction: Not provided in the supplied data.
  • Filing timeliness: Reported and filed with period date 2026-09-09 — appears timely (no late-file flag shown).

Context

  • These dispositions are corporate-merger related (scheme of arrangement) and should not be read as a routine insider cash sale. The Form 4 reports conversion/assumption activity (including option conversions) under the Merger Agreement rather than open-market trading. For retail investors, merger-driven conversions are neutral operational events: they change the security held (Barinthus → Topco) rather than indicate insider sentiment via cash-in transactions.

AI-written summary · check the filing